Sleep Medicine, Neuromuscular, and Skeletal

Tirzepatide's approval for moderate-to-severe OSA raises a genuinely new question: when PAP therapy is effective but a patient won't reliably use it, does starting a slower-acting drug instead of the fast-acting standard trade an immediate safety risk for a treatment he might actually keep taking?

Residual sleep apnea despite good PAP adherence, and early diabetic kidney disease, sit in the same patient at the same visit. Tirzepatide, semaglutide, and an SGLT2 inhibitor each have their strongest evidence pointed at a different one of his problems.

A sleep study recommends adaptive servo-ventilation for Cheyne-Stokes breathing before anyone checks it against a well-established mortality signal in exactly this population.

Acetazolamide has strong evidence for one of this patient's two breathing problems and thin evidence for the other — and the two are easy to conflate because they share a chemoreceptor mechanism.

Weight loss is the only therapy that reverses obesity hypoventilation syndrome rather than just supporting it — but the specific way GLP-1/GIP agents produce that weight loss carries a real, mechanism-specific risk for a patient whose respiratory muscles are already working at a deficit.

A disease-modifying ALS therapy's pivotal trial enrolled patients earlier in disease and with stronger lung function than this patient has now. What that mismatch should mean for the conversation, and what actually helps him today, are separable questions.